

Betulinic acid induces cell death by necrosis in *Trypanosoma cruzi*



Paloma Leão Sousa^a, Racquel Oliveira da Silva Souza^a, Louise Donadello Tessarolo^a,
Ramon Róseo Paula Pessoa Bezerra de Menezes^b, Tiago Lima Sampaio^b, Jader Almeida Canuto^a,
Alice Maria Costa Martins^{a,*}

^a Department of Clinical and Toxicological Analysis, Federal University of Ceará, Fortaleza, Ceará, Brazil

^b Department of Physiology and Pharmacology, Federal University of Ceará, Fortaleza, Ceará, Brazil

ARTICLE INFO

Keywords:

Betulinic acid
Chagas disease
Trypanosoma cruzi
Necrosis

ABSTRACT

Chagas' disease is a neglected disease caused by the protozoan parasite *Trypanosoma cruzi* and constitutes a serious health problem worldwide. The treatment is limited, with variable efficacy of benznidazole and nifurtimox. Betulinic Acid (BA), a triterpene, can be found in medicinal herbs and has a wide variety of biological and pharmacological activities. The objective was to evaluate betulinic acid effects on the cell death mechanism in *Trypanosoma cruzi* strain Y. BA inhibited the growth of epimastigotes in periods of 24 h (IC₅₀ = 73.43 μM), 48 h (IC₅₀ = 119.8 μM) and 72 h (IC₅₀ = 212.2 μM) of incubation; of trypomastigotes (IC₅₀ = 51.88 μM) in periods of 24 h and intracellular amastigotes (IC₅₀ = 25.94 μM) in periods of 24 and 48 h of incubation, no toxicity on LLC-MK₂ cells at the concentrations used. Analysis of the possible mechanism of parasite cell death showed alterations in mitochondrial membrane potential, alterations in cell membrane integrity, an increase in the formation of reactive oxygen species and increase swelling of the reservosomes. In conclusion, betulinic acid was able to inhibit all developmental forms of *Trypanosoma cruzi* Y strain with necrotic mechanism and involvement of mitochondrial membrane potential alteration and increase in reactive oxygen species.

1. Introduction

Chagas' disease is one of the seventeen Neglected Tropical Diseases (NTDs), caused by the parasite *Trypanosoma cruzi*. It is considered one of the greatest public health problems in Latin America and an estimated 7 million individuals are infected with *T. cruzi* worldwide, causing more than 7000 deaths a year (WHO, 2015). Benznidazole and nifurtimox, drugs used for the treatment, have important side effects and limited efficacy (Bermudeza et al., 2016). Thus, the search for new therapeutic agents it is necessary.

Betulinic acid (BA), a pentacyclic lupane-type triterpene, is widely found in the medicinal herbs and plants. BA and/or its derivatives exhibits a wide variety of biological and pharmacological activities, including anti-human immunodeficiency virus (HIV), antibacterial, anti-malarial, anti-inflammatory, anthelmintic, antinociceptive, anti-herpes simplex viruses-1 (HSV-1), immune-modulatory, antiangiogenic and anticancer activity (Lee et al., 2015). Furthermore, it has been demonstrated that betulinic acid derivatives inhibit growth of epimastigote forms *T. cruzi* strain Tulahuen (Domínguez-Carmona et al., 2010) and reduces the viability of trypomastigote forms of *T. cruzi* strain Y (Meira et al., 2016). In this short communication, it is reported the

effect of betulinic acid on cell death mechanism in *Trypanosoma cruzi* strain Y.

2. Materials and methods

2.1. Trypanocidal activity of betulinic acid

Epimastigote forms of *T. cruzi* Y strain were plated in LIT medium (HiMedia Laboratories, Mumbai, IND) supplemented with 10% FBS and antibiotics (100 IU/mL Penicillin and 100 μg/mL streptomycin). Trypomastigote forms were obtained from infected LLC-MK2 cells in T-25/75 cm² sterile flasks using DMEM medium (Vitrocell, São Paulo, Brazil) supplemented with 1% antibiotics and 2% of FBS, cultured at 37 °C in an atmosphere with 5% CO₂ (Aparicio et al., 2004) for 24 h. Both epimastigote and trypomastigote forms were incubated in the presence of BA (Sigma–Aldrich™, St. Louis, USA) (1.56, 3.12, 6.25, 12.5, 25, 50, 100, 200 μM) or benznidazole (BZ; ROCHE, São Paulo, BR) (1.56, 3.12, 6.25, 12.5, 25, 50 μg/mL) for 24, 48 and 72 h (epimastigote) and 24 h (trypomastigote) in culture conditions. Parasite growth inhibition was quantified in a Neubauer chamber (Rodrigues et al., 2014; Adade et al., 2014).

* Corresponding author.

E-mail address: martinsalice@gmail.com (A.M.C. Martins).

To evaluate the action of BA on the amastigote form, the LLC-MK2 cells were seeded in well plates containing glass coverslips cultivated in DMEM medium, supplemented with 10% FBS and antibiotics for 24 h at 37 °C in a 5% CO₂. Furthermore, the cells were infected with trypomastigote forms at 5 × 10⁶ parasite/mL in DMEM medium supplemented with 2% FBS. After 48 h of infection, the parasites were washed with PBS to remove the non-interiorized parasites. After that, the infected LLC-MK2 cells were treated with BA at concentrations of 25.94 μM (½ IC₅₀) and incubated for 24 and 48 h. The coverslips were washed with PBS, fixed in Bouin's solution, stained with Giemsa and permanently mounted. The number of intracellular amastigotes per 100 cells was determined by counting 300 cells in triplicate (Zingales et al., 1998; Zingales et al., 1997; Andrews and Colli, 1982).

2.2. Cytotoxicity assay of betulinic acid against LLC-MK2 cells

LLC-MK2 cell were plated in DMEM medium supplemented with 10% FBS and antibiotics, and then incubated in a 5% CO₂ at 37 °C for 24 h. The cells were then incubated with BA (200, 400, 800 and 1600 μM) and BZ (1.56, 3.12, 6.25, 12.5, 25, 50 μg/mL) for 24 h. Cell viability was measured using a standard MTT assay (AMRESCO, Ohio, USA) (Mosmann, 1983). The absorbance at 570 nm was analyzed in a microplate reader (Biochrom® Asys Expert Plus). Cell viability was calculated in comparison with the control group.

2.3. Mechanism of action evaluation

- Cytometry flow analysis:** in order to evaluate BA action mechanism, treated cells were analyzed by flow cytometry after staining with specific markers. It was used a FACSCalibur flow cytometer and at least 10,000 live events were counted and analyzed using Cell Quest software (Becton-Dickinson, San Jose, CA). Epimastigote forms treated with BA (73.43 μM) for 24 h were stained with annexin V-PE/7-AAD according to the manufacturer's instructions (BD Biosciences, California, USA) to evaluate cell death by apoptosis or necrosis. For mitochondrial transmembrane potential evaluation, treated parasites were analyzed after Rhodamine 123 labeling (10 μg/mL). Reactive Oxygen Species (ROS) measurement was also assessed, using DCFH-DA (20 mM). For investigation of reservoir swelling, acridine orange (5 μg/mL) was used as marker of acidic vesicles.
- Confocal microscopy:** Epimastigote forms were incubated with IC₅₀ (73.43 μM) of BA for 24 h at 28 °C. After that, the parasites were washed and labeled with Rhodamine 123 (10 μg/mL) to assess the mitochondrial transmembrane potential. The cells were analyzed under a LSM 710 confocal laser scanning microscope (Zeiss, Germany).

2.4. Statistical analysis

The data were expressed as SEM of at least three independent experiments and were analyzed using two-way or one-way analysis of variance (ANOVA) followed by Bonferroni post-tests or Student's *t*-test. Values of *p* ≤ 0.05 were considered statistically significant. Growth capacity 50% of the cellular growth (IC₅₀) estimated by non-linear regression and the percentage of viable parasites. The statistical analysis was performed using GraphPad Prism 5.0 program (GraphPad Software, San Diego, CA, USA).

3. Results and discussion

In the present study, the strain Y of *T. cruzi* was selected, since presents partial resistance to benznidazole (Cherkesova et al., 2014). BA inhibited the growth of epimastigote forms after 24, 48 and 72 h incubation (1.96–200 μM) and reduced the viability of trypomastigote forms after 24 h of treatment (Table 1). These data corroborate

previous studies assessing the effect of betulinic acid and its derivatives on epimastigote forms of *T. cruzi* strain Tulahuen (Domínguez-Carmona et al., 2010) and trypomastigote forms of *T. cruzi* strain Y (Meira et al., 2016).

To evaluate the cytotoxic effects of BA, LLC-MK2 cells were treated with different concentrations of BA using the MTT assay. It wasn't observed toxicity on cells at the concentrations used (Fig. 1A). The IC₅₀ was 391.8 μM after 24 h treatment (Table 1). The IC₅₀ was compared with the activity against trypomastigotes (IC₅₀), yielding the selectivity index (SI; ratio of the IC₅₀ in LLCMK₂ cells to the IC₅₀ in protozoa). BA was shown to be more toxic to the protozoa than to mammalian cells (SI = 7.5 for trypomastigotes) (Table 1). The BA showed a superior selectivity index than benznidazole, the standard drug, and exhibited a potential selectivity when tested on LLC-MK₂.

The present study shows for the first time the effects of BA on intracellular forms of *T. cruzi*, with decrease on the number of amastigote per 100 cells (Fig. 1B) and the percentage of infected cells (Fig. 1C) after 24 and 48 h of incubation (25.94 μM), when compared to untreated infected cells with BA. BZ, the reference drug, also caused anti-amastigote activity, with 64.4 ± 3.6% of infected cells at 257 μM and 48.8 ± 5.5% at 514 μM.

BA trypanocidal effect is supported by other studies, where it displays antiparasitic effect on other protozoa, as such as *Leishmania major* (Begum et al., 2014), *L. tarentolae* and *Plasmodium falciparum* (Graziose et al., 2012). Furthermore, AB and its derivatives also have shown leishmanicidal effect on promastigote forms of *L. amazonensis*, *L. braziliensis* and *L. donovani* (Domínguez-Carmona et al., 2010).

After this, flow cytometry assays were performed to evaluate changes on morphological and biochemical characteristics on *T. cruzi* cells treated with BA. These changes are useful to identify specific cell death profiles and identify BA biological effect. Some events, as loss of plasma membrane integrity, characterize necrotic mechanisms, while externalization of phosphatidylserine (PS) and loss of mitochondrial membrane potential (ΔΨ_m) occurs in apoptotic cells (Menna-Barreto and Castro, 2015).

Experiments using stained-Rho 123 epimastigotes were performed to evaluate ΔΨ_m. It was observed a decrease on Rho 123 accumulation after treatment with BA (73.43 μM), as shown by flow cytometry (Fig. 1D) and by confocal microscopy (Fig. 1E). This data suggests alteration on mitochondrial transmembrane potential in BA-treated parasites. In addition, it was observed an increase on ROS production (Fig. 1F), verified by enhance on DCF-labeled cells.

Additionally, *T. cruzi* cells were stained with acridine orange (AO) after treatment with BA. This dye accumulates in acidic compartments, and it is used as a marker of reservoir swelling on hemoflagellate parasites (Klionsky et al., 2016). In this study, it was observed an increase on the level of AO labeling, indicating reservoir swelling. This event is characteristic of autophagic mechanisms, through permeabilization of acidic vesicles and enzymatic digestion of intracellular components (Krysko et al., 2008).

Finally, 7-AAD and annexin V were used as markers of necrosis and apoptosis, respectively. As shown in Fig. 1H, epimastigote forms treated with BA exhibited a significant increase in double-marked (DM) fluorescence and, especially, those marked with 7AAD fluorescence intensity after 24 h of treatment compared with untreated parasites.

Altogether, the results demonstrates that BA effect on *T. cruzi* epimastigotes is related to necrosis induction, with increase on ROS production, loss of mitochondrial integrity and reservoir swelling. These data corroborate with previous studies, that demonstrated that betulinic acid causes death in *T. cruzi* trypomastigotes mainly by necrosis (Meira et al., 2016). In contrast, BA causes phosphatidylserine externalization and DNA fragmentation assays in *Leishmania infantum* promastigote forms (Sousa et al., 2014), suggesting that different cell death mechanisms may be involved on its action mechanisms on parasites.

In conclusion, betulinic acid was able to inhibit all developmental

Table 1
Anti-parasitic activity of Betulinic Acid on *T. cruzi* and host cell cytotoxicity.

	Epimastigote (<i>T. cruzi</i>)		Trypomastigote (<i>T. cruzi</i>)		LLC-MK ₂ ^a		SI	
	BA IC ₅₀ ± SEM (µM)	BZ IC ₅₀ ± SEM (µM)	BA IC ₅₀ ± SEM (µM)	BZ IC ₅₀ ± SEM (µM)	BA IC ₅₀ ± SEM (µM)	BZ IC ₅₀ ± SEM (µM)	BA	BZ
24 h	73.43 ^(± 0.09)	218 ^(± 55)	51.88 ^(± 0.14)	25 ^(± 20)	391.8 ^(± 0.05)	616 ^(± 61)	7.5	2.3
48 h	119.8 ^(± 0.06)	61 ^(± 10)	-	-	-	-	-	-
72 h	212.2 ^(± 0.13)	16.5 ^(± 3)	-	-	-	-	-	-

BA = betulinic acid. BZ = benznidazole. IC₅₀ = inhibitory concentration at 50%. SI = Selective index. SEM = Standard error mean. Values are expressed as mean ± SEM of three independent experiments performed in triplicate.

^a Cell viability of LLC-MK₂ determined 24 h after treatment.




Fig. 1. (A) Cytotoxic effect of Betulinic Acid (BA) for 24 h on LLC-MK₂ cells in MTT assay. (B) Effect of BA on amastigote/100 cells counting after 24 and 48 h of incubation. (C) Effect of BA on percentage of infected cells after 24 and 48 h of incubation. (D) Evaluation of mitochondrial transmembrane potential ($\Delta\Psi_m$) of epimastigote forms treated with BA for 24 h measured by Rhodamine 123 by flow cytometry analysis. (E) Evaluation of mitochondrial transmembrane potential ($\Delta\Psi_m$) of epimastigote forms treated with BA (IC₅₀) for 24 h measured by Rhodamine 123 staining with confocal laser scanning microscopy. (F) Total ROS production of epimastigote forms treated with BA for 24 h and stained with the cell-permeable probe H₂DCFDA staining, by flow cytometry. (G) Epimastigote forms treated with BA for 24 h and stained with the cell-permeable probe Orange Acridine (OA) by flow cytometry analysis. (H) Evaluation of cell death pathway of epimastigote forms treated with BA for 24 h measured by annexin V (AX) and 7AAD staining and detected by flow cytometry. Values are expressed as mean ± SEM of three independent experiments performed in triplicate. *Significantly different from the control group (two-way and one-way ANOVA and Bonferroni post-test; Student's *t*-test **p* < 0.05).

forms of *Trypanosoma cruzi* Y strain. Additionally, its mechanism is related to necrotic induction, mitochondrial membrane potential disruption, increase on ROS production and reservosome swelling.

Conflicts of interest

No conflicts of interest are declared.

Acknowledgements

The authors thank National Council of Technological and Scientific Development (CNPq) and Coordination for Enhancement of Higher Education Personnel (CAPES) for their financial support.

References

- Adade, C.M., Carvalho, A.L., Tomaz, M.A., Costa, T.F., Godinho, J.L., Melo, P.A., et al., 2014. Crovirin, a snake venom cysteine-rich secretory protein (CRISP) with promising activity against Trypanosomes and Leishmania. *PLoS Negl. Trop. Dis.* 8, e3252.
- Andrews, N.W., Colli, W., 1982. Adhesion and interiorization of *Trypanosoma cruzi* in mammalian cells. *J. Protozool.* 29, 264–269.
- Begum, S., Ayub, A., Qamar Zehra, S., Shaheen Siddiqui, B., Iqbal Choudhary, M., Samreen, 2014. Leishmanicidal triterpenes from *lantana camara*. *Chem. Biodivers.* 11 (5), 709–718.
- Bermudeza, J., Daviesb, C., Simonazzia, A., Realc, J.P., Palma, S., 2016. Current drug therapy and pharmaceutical challenges for Chagas disease. *Acta Trop.* 156, 1–16.
- Cherkesova, T.S., Hargrove, T.Y., Vanrell, M.C., Ges, I., Usanov, S.A., Romano, P.S., Lepesheva, G.I., 2014. Sequence variation in CYP51A from the y strain of *Trypanosoma cruzi* alters its sensitivity to inhibition. *FEBS Lett.* 588, 3878–3885.
- Domínguez-Carmona, D.B., Escalante-Erosa, F., García-Sosa, K., Ruiz-Pinell, G., Gutierrez-Yapu, D., Chan-Bacab, M.J., Gimenez-Turba, A., Penã-Rodríguez, L.M., 2010. Antiprotozoal activity of Betulinic acid derivatives. *Phytomedicine* 17, 379–382.
- Graziose, R., Rojas-Silva, P., Rathinasabapathy, T., Dekock, C., Grace, M.H., Poulev, A., Ann Lila, M., Smith, P., Raskin, I., 2012. Antiparasitic compounds from *Cornus florida* L. with activities against *Plasmodium falciparum* and *Leishmania tarentolae*. *J. Ethnopharmacol.* 142 (2), 456–461.
- Klionsky, D.J., Abdelmohsen, K., Abe, A., Abedin, M.J., Abeliovich, H., Acevedo Arozena, A., et al., 2016. Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy* 12 (1), 1–222 3rd edition.
- Krysko, D.V., Vanden Berghe, T., D'Herde, K., Vandenabeele, P., 2008. Apoptosis and necrosis: detection: discrimination and phagocytosis. *Methods* 44, 205–221.
- Lee, S.Y., Kim, H.H., Park, S.U., 2015. Recent studies on betulinic acid and its biological and pharmacological activity. *EXCLI J.* 14, 199–203.
- Meira, C.S., Barbosa-Filho, J.M., Lanfredi-Rangel, A., Guimarães, E.T., Moreira, D.R.M., Soares, M.B.P., 2016. Antiparasitic evaluation of betulinic acid derivatives reveals effective and selective anti-*Trypanosoma cruzi* inhibitors. *Exp. Parasitol.* 166, 108–115.
- Menna-Barreto, R.F.S., Castro, S.L., 2015. Between armour and weapons—cell death mechanisms in trypanosomatid parasites. In: Ntuli, T.M. (Ed.), *Biochemistry, Genetics and Molecular Biology » Cell Death – Autophagy, Apoptosis and Necrosis*. InTech. <http://dx.doi.org/10.5772/61196>. Available from: <http://www.intechopen.com/books/cell-death-autophagy-apoptosis-and-necrosis/between-armour-and-weapons-cell-death-mechanisms-in-trypanosomatid-parasites>.
- Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity. *J. Immunol. Methods* 65, 55–63.
- Rodrigues, J.H., Ueda-Nakamura, T., Correa, A.G., Sangi, D.P., Nakamura, C.V., 2014. A quinoxaline derivative as a potent chemotherapeutic agent, alone or in combination with benzimidazole, against *Trypanosoma cruzi*. *PLoS One* 9, e85706.
- Sousa, M.C., Varandas, R., Santos, R.C., Santos-Rosa, M., Alves, V., Salvador, J.A.R., 2014. Antileishmanial activity of semisynthetic lupane triterpenoids betulin and betulinic acid derivatives: synergistic effects with miltefosine. *PLoS One* 9, e89939.
- WHO/Department of control of neglected tropical diseases, 2015. Investing to overcome the global impact of neglected tropical diseases: third WHO report on neglected diseases. In: Chairman, P.H. (Ed.), *World Health Organization's Department of Control of Neglected Tropical Diseases*. Available from: http://www.who.int/neglected_diseases/9789241564861/en/.
- Zingales, B., Pereira, M.E., Oliveira, R.P., Almeida, K.A., Umezawa, E.S., Souto, R.P., Vargas, N., Cano, M.I., Da Silveira, J.F., Nehme, N.S., Morel, C.M., Brener, Z., Macedo, A., 1997. *Trypanosoma cruzi* genome project: biological characteristics and molecular typing of clone CL Brener. *Acta Trop.* 68, 159–173.
- Zingales, B., Souto, R.P., Mangia, R.H., Lisboa, C.V., Campbell, D.A., Coura, J.R., Jansen, A.M., Fernandes, O., 1998. Molecular epidemiology of American trypanosomiasis in Brazil based on dimorphisms of rRNA and mini-exon gene sequences. *Int. J. Parasitol.* 28, 105–112.